OpenNashPodcasts

Person

Brice Challamel

Brice Challamel is a Moderna executive who spoke on the Eye On A.I. podcast (episode #249) about how the company uses artificial intelligence in healthcare, from mRNA design to personalized cancer treatment. Before Moderna, he worked at Boston Consulting Group, at L'Oréal in marketing, and for five years at Google Cloud as global head of transformation.

Challamel told the podcast that Moderna has about 1,800 GPTs in production and more than 50 ongoing clinical trials. He also described its personalized cancer medicines as being in phase three trials, and said he sees five basic uses of AI: perception, categorization, prediction, recommendation and generation.

1 episodes · 24 quoted claims

Moderna has about 1,800 GPTs in production, according to Brice Challamel.

“We have about 1 ,800 GPs in production at Moderna. We probably have as many AI solutions, which are applications calling APIs from different models to a platform”

Eye On A.I. · 0:08:51

Brice Challamel estimates Moderna has roughly 4,000 to 5,000 internal AI products in total.

“The combination of all those products is probably around 4 ,000 to 5 ,000.”

Eye On A.I. · 0:08:51

Moderna's internal machine learning platform is called Compute and its API orchestrator is called MChat.

“an ML platform, which is called Compute, and our API orchestrator, which is called MChat.”

Eye On A.I. · 0:08:51

Brice Challamel says the number of possible mRNA designs for a single protein exceeds the number of atoms in the universe, a challenge he compares to the game of Go.

“There are more ways to design an mRNA that calls a protein one specific protein than there are atoms in the universe the same type of challenge as the go game.”

Eye On A.I. · 0:10:34

Moderna has more than 50 ongoing clinical trials, according to Brice Challamel.

“we have more than 50 ongoing clinical trials. You can check them out. They're on our website.”

Eye On A.I. · 0:00:00

Moderna's Brice Challamel says clinical trials with mRNA technology began in 2001, although the design dates from the 1950s.

“We started doing clinical trials with mRNA technology in 2001, even though the design dates from the 50s.”

Eye On A.I. · 0:22:26

Brice Challamel says Moderna has two mRNA vaccines, for COVID and RSV, and is the only company with two mRNA products.

“Today, we have two mRNA vaccines, one for COVID and one for RSV. And we are the only company in the world to have two mRNA products.”

Eye On A.I. · 0:22:26

Pfizer has an mRNA-based COVID vaccine, but its RSV vaccine uses traditional vaccine technology, according to Brice Challamel.

“Pfizer also has a COVID vaccine that is based on mRNA, but their RSV vaccine is a traditional vaccine technology.”

Eye On A.I. · 0:22:26

Brice Challamel says no mRNA therapy was on the market when the COVID pandemic began.

“There was no mRNA therapy on the market when COVID broke.”

Eye On A.I. · 0:22:26

Moderna develops its cancer treatments in partnership with Merck.

“Our oncology practice, our cancer treatments is done in partnership with Merck.”

Eye On A.I. · 0:18:50

Brice Challamel says the FDA published draft guidance on AI usage in January.

“The FDA has published a draft guidance on AI usage for various use cases in January.”

Eye On A.I. · 0:29:57

The FDA worked with Moderna on approval of the COVID vaccine, which Brice Challamel describes as the first mRNA product to reach the American market.

“They were an amazing partner to Moderna in the approval process of the very first mRNA product ever to go to market in America, which was the COVID vaccine.”

Eye On A.I. · 0:28:54

Moderna's personalized cancer medicines are in phase three clinical trials, according to Brice Challamel.

“we are right now in phase three clinical trials and personalized cancer medicines.”

Eye On A.I. · 0:33:47

Moderna's personalized cancer therapy starts with a biopsy to find unusual tumor proteins called neoantigens.

“we do a biopsy of the cancer cells and we look at the proteins in those cells that are unusual that are the outcome of the cancer itself these are called neo-antigents”

Eye On A.I. · 0:33:47

Moderna generates an mRNA that codes the identified tumor proteins so the immune system targets cancer cells.

“we generate an mRNA that codes those proteins and that points the immune system to cancer cells”

Eye On A.I. · 0:33:47

Moderna's personalized cancer treatment approach is called INT, short for Individualized Neo-Antigen Therapy.

“So this is called INT, Individualized Neo-Antigen Therapy.”

Eye On A.I. · 0:38:52

Moderna expects to produce about 200 vials per personalized therapy, of which about a dozen would be used by the patient, with the rest kept for traceability.

“we are likely to propose to the order of 200 vials of the medicine, out of which a dozen is going to be used by the patient”

Eye On A.I. · 0:39:35

Moderna chose to market its COVID vaccine itself, while BioNTech went to market through Pfizer.

“Moderna made the decision to go to market by ourselves. BioNTech didn't have that luxury, was too small probably at the time, and went to market through Pfizer.”

Eye On A.I. · 0:42:26

Brice Challamel describes Moderna as emerging from the Flagship venture ecosystem and the community around Harvard Medical School.

“Flagship, which is our venture capital and finance birth ecosystem that produces dozens of biotech startups and as modern as one of their crown jewels.”

Eye On A.I. · 0:44:00

Brice Challamel compares generative AI to the graphical interface for computers, which moved computing from typed Unix commands to mouse-based interaction.

“Before that, you had to type commands in Unix, and then you could just click on the mouse and drag and drop objects, and you had Visual Basic”

Eye On A.I. · 0:12:17

Brice Challamel says AI at the time Moderna was founded was mostly machine learning.

“back in the 2010s when Moderna was founded, AI at the time was mostly machine learning.”

Eye On A.I. · 0:12:49

Before Moderna, Brice Challamel worked as a consultant at Boston Consulting Group and in marketing at L'Oréal.

“I was a consultant at the Boston Consulting Group and I worked in marketing in a consumer brand called L 'Oréal.”

Eye On A.I. · 0:03:26

Brice Challamel spent five years at Google Cloud as global head of transformation before joining Moderna.

“I worked at Google Cloud for five years as global head of transformation”

Eye On A.I. · 0:02:49

Brice Challamel identifies five fundamental uses of AI: perception, categorization, prediction, recommendation and generation.

“I know five of them. and I've never met another and I've been doing this for more than a decade now.”

Eye On A.I. · 0:23:42